SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

Fresenius Kabi USA logo
6 days ago

Manager, Marketing

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)Full time$105K/yr – $130K/yr
Fresenius Kabi USA logo
3 weeks ago

Marketing Manager (Biosimilars)

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)Full time$105K/yr – $130K/yr
Fresenius Kabi USA logo
3 months ago

Manager, Marketing (DTC)

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)Full time$115K/yr – $135K/yr
Fresenius Kabi USA logo
3 months ago

Manager, Marketing (E-Commerce)

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)Full time$115K/yr – $135K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Fresenius Kabi USA logo

Manager, Marketing

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)

$105K/yr - $130K/yrIn-houseFull-timeManager5+ years exp.
6 days ago
Fresenius Kabi USA logo

Marketing Manager (Biosimilars)

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)

$105K/yr - $130K/yrIn-houseFull-timeManager5+ years exp.
3 weeks ago
Fresenius Kabi USA logo

Manager, Marketing (DTC)

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)

$115K/yr - $135K/yrIn-houseFull-timeManager8+ years exp.
3 months ago
Fresenius Kabi USA logo

Manager, Marketing (E-Commerce)

Fresenius Kabi USA

Lake Zurich, IL (Hybrid)

$115K/yr - $135K/yrIn-houseFull-timeManager8+ years exp.
3 months ago
Fresenius Kabi USA logo
Fresenius Kabi USA

Manager, Marketing

Lake Zurich, IL (Hybrid)

$105K/yr – $130K/yrManager5+ years expFull time

Posted 6 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the development and execution of provider-focused marketing across channels, leveraging cross-functional collaboration to drive awareness, engagement, and business outcomes in biosimilars.

  • Lead cross-functional collaboration with sales, regulatory, and medical affairs
  • Develop provider-specific messaging and collateral across channels
  • Analyze customer data to refine tactical and strategic execution

Job Description

Responsibilities

  • Work with cross-functional teams (e.g. National & Regional Account teams, regulatory, legal, medical communications, medical, market research, market access, sales operations and sales training teams).
  • Utilize insights to develop provider-specific messaging & deliver actionable marketing collateral across marketing channels, to drive customer awareness and engagement.
  • Generate and analyze customer data/insights to continue to evolve and improve tactical and strategic execution.
  • Actively contribute to design, development and implementation of GPO initiatives and marketing opportunities that support the biosimilars portfolio, including personal and non-personal promotion, product theatres, etc.
  • Support the development of strategically targeted and efficient media plans to reach high value customer segments.
  • Assess market dynamics and competitive activity.
  • Establish highly effective, collaborative working relationship with sales and sales leadership to ensure that field insights are heard and incorporated into marketing tactics as aligned to customer strategies.
  • Develop content and collaborate with sales training to ensure effective training on promotional tools and materials.
  • Support congress activities and GPO meetings, when applicable.
  • Support sales meeting planning and execution.

Requirements

  • Bachelors Degree required; advanced science or business degree a plus.
  • 5+ years Pharma experience required.
  • Competency in core marketing capabilities such as resource development, positioning and optimization across the marketing mix.
  • Strong interpersonal skills, organizational skills, teamwork and collaboration skills; proven ability to influence cross-functional teams, including timeline and budget management.
  • Strong verbal and written communication skills.
  • Ability to multitask and work within deadlines, professionally managing competing priorities.
  • Buy-and-bill/medical benefit experience a plus.
  • The Company’s primary business language is English. The successful candidate must be able to effectively speak, read, write, and understand English to perform the essential functions of the position, including independently understanding policies, procedures, training materials, and workplace communications written in English due to our heavily regulated work environment.

Benefits

  • We offer an excellent salary and benefits package including medical, dental and vision coverage, as well as life insurance, disability, 401K with company contribution, and wellness program.
Fresenius Kabi USA logo

Fresenius Kabi USA

3.9 Glassdoor

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 43,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies.In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care.Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of almost 450 million patients annually. With Vision 2026, as part of the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale.For more information, please visit www.fresenius-kabi.com/us.

Founded in 1999
Lake Zurich, Illinois, USA
1.7K employees (104 in marketing)
www.fresenius-kabi.com/us
78% recommend to a friend
80% CEO approval

Traffic Signals

Monthly Visitors
206.9K
Monthly Google Ads Budget
$3.2K
Traffic Source Mix
Search
57.9%
Direct
33.1%
Referral
6%
Social
1.9%
Paid
0.9%

Headcount Trend

Current headcount: ~1.7K

Marketing Team

Marketing Team Size
85 (5% of company)
Median Career Experience
19 years
Median Tenure
6.6 years
Marketing Roles Posted (Last 30 Days)
2

People

HR / Recruitment

Deanna Cato Phr
Deanna Cato Phr
HR/Project Manager
At the company for 17 years 1 month
Diane Francke
Diane Francke
Sr HR Manager

Marketing Leadership

Angie Lindsey
Angie Lindsey
Vice President Marketing
At the company for 14 years 5 months
Eric Sato
Eric Sato
Vice President Marketing
At the company for 3 years 9 months
Dennis Preusker
Dennis Preusker
Vice President Marketing
At the company for 9 years 3 months
Kaushik Lakkaraju
Kaushik Lakkaraju
Vice President - Portfolio & Strategic Marketing, Region NAM
At the company for 15 years 1 month

Recent News

Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers
Nov 12, 2025 • Business Wire
Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
Nov 7, 2025 • Morningstar
FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence
Oct 29, 2025 • Business Wire
Fresenius Kabi Announces 13 New Inductees Into the National Blood Donation Hall of Fame
Oct 22, 2025 • Business Wire
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Conexxence® and Bomyntra® (denosumab-bnht)
Sep 29, 2025 • Business Wire
Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®
Sep 25, 2025 • Business Wire
Fresenius Kabi and AABB Announce 20th Anniversary of Blood Collectors Week, September 7–14, 2025, Honoring Lifesaving Blood Collection Professionals
Sep 7, 2025 • Business Wire
Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
Aug 26, 2025 • Business Wire
Fresenius Expands Biosimilars Portfolio with Denosumab Biosimilars in the U.S.
Jul 1, 2025 • Contract Pharma
Fresenius Expands Biosimilars Portfolio With The Launch of Denosumab Biosimilars in the U.S.
Jul 1, 2025 • Business Wire
Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials
May 20, 2025 • Business Wire
FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi® (ustekinumab-aauz)
May 19, 2025 • Business Wire
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
May 5, 2025 • Business Wire
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi® (ustekinumab-aauz)
Apr 28, 2025 • Business Wire
Fresenius’ Misconduct Defense Fails in PharmaSphere Patent Case
Apr 1, 2025 • Bloomberg Law News
Fresenius Receives FDA Approval for their Denosumab Biosimilars and Secures Global Settlement Agreement
Mar 27, 2025 • Business Wire
Fresenius Kabi, Formycon Launch Otulfi in U.S.
Mar 20, 2025 • Contract Pharma
Amgen, Fresenius Settle Osteoporosis Drug Patent Dispute
Mar 10, 2025 • Law360
Amgen and Fresenius Kabi Settle US BPCIA Denosumab Litigation
Mar 7, 2025 • Pearce IP
Update on Alert: Infusion Pump Issue from Fresenius Kabi USA
Mar 5, 2025 • fda.gov
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)
Mar 3, 2025 • Business Wire
Fresenius Kabi Introduces Calcitonin Salmon Injection, USP Synthetic
Feb 10, 2025 • Business Wire
Fresenius Kabi Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora Xi Plasmapheresis System
Jan 28, 2025 • Business Wire
Fresenius Kabi Launches Epinephrine Injection, USP Expanding U.S. Pharma Portfolio
Dec 17, 2024 • Business Wire
Fresenius Kabi Launches Generic Epinephrine Injection in U.S.
Dec 17, 2024 • Contract Pharma
FDA Warns About Failure Risks with Fresenius Ivenix Infusion Pumps
Dec 12, 2024 • AboutLawsuits.com
Fresenius Kabi warns on Ivenix infusion pump valves
Dec 11, 2024 • Drug Delivery Business
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code and Pass-Through Payment Status for Tyenne
Oct 29, 2024 • Business Wire